ReviewCureus2025
The Impact of Drug Delivery Systems on Pharmacokinetics and Drug-Drug Interactions in Neuropsychiatric Treatment.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rhizomes as Multi-Target Pharmacological Platforms Against Tauopathy: Neuro-Metabolic Crosstalk, Drug-Likeness, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Redefining long-acting injectables: the emerging role of extracellular vesicles in sustained drug delivery.Drug delivery and translational research · 2026Review
- Developing a Chitosan/polyvinyl alcohol hydrogel for gastro-retentive release of ranitidine and enhanced anti-ulcerative properties.BMC biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropsychiatric drugs are essential for the management of mental health disorders, yet their therapeutic effectiveness is often compromised by complex pharmacokinetics (PK), significant drug-drug interactions (DDIs), limited blood-brain barrier (BBB) penetration, and poor patient adherence. Advanced drug delivery systems (DDSs) offer innovative strategies to overcome these challenges by improving drug solubility, targeting, release kinetics, and systemic exposure profiles. This review critically examines the impact of DDS on the PK and DDI profiles of psychotropic medications, highlighting key technologies such as nanoparticles, transdermal systems, prodrugs, depot formulations, implantables, and smart delivery platforms. By enhancing drug bioavailability and CNS targeting while minimizing systemic toxicity and DDI risks, these systems enable more consistent therapeutic outcomes across diverse neuropsychiatric conditions. This review also explores the integration of DDS with personalized medicine approaches - pharmacogenomics, biomarker-driven delivery, and artificial intelligence - to facilitate tailored treatment strategies. Furthermore, it addresses practical challenges including regulatory hurdles, cost and accessibility, long-term safety data, and patient education. Through interdisciplinary innovation and strategic implementation, DDSs are poised to revolutionize neuropsychiatric pharmacotherapy by offering safer, more effective, and patient-centric solutions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.